Clinical efficacy of first and second series of peptide receptor radionuclide therapy in patients with neuroendocrine neoplasm: a cohort study

Peptide receptor radionuclide therapy (PRRT) is an established treatment for metastatic neuroendocrine neoplasms (NEN). However, only limited data exists for the effect of multiple series of PRRT. The aim of this study was to investigate PFS and OS inNEN patients treated with multiple series of PRRT...

Full description

Saved in:
Bibliographic Details
Published in:Scandinavian journal of gastroenterology 2021-03, Vol.56 (3), p.289-297
Main Authors: Zacho, M. D., Iversen, P., Villadsen, G. E., Baunwall, S. M. D., Arveschoug, A. K., Grønbaek, H., Dam, G.
Format: Article
Language:English
Subjects:
Aged
bronchopulmonary tumors
Cohort Studies
Female
first and second series
gastropancreatic tumors
Humans
Male
Middle Aged
Neuroendocrine
Neuroendocrine Tumors - radiotherapy
peptide receptor radionuclide therapy
Radioisotopes - therapeutic use
Receptors, Peptide
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Peptide receptor radionuclide therapy (PRRT) is an established treatment for metastatic neuroendocrine neoplasms (NEN). However, only limited data exists for the effect of multiple series of PRRT. The aim of this study was to investigate PFS and OS inNEN patients treated with multiple series of PRRT conforming to the ENETS treatment protocol. We included all patients with gastrointestinal (GI), pancreatic and bronchopulmonary (BP) NEN treated with PRRT from 2008 to 2018. We used Kaplan-Meier estimation to evaluate PFS and OS with subgroup analysis of primary tumor, Ki67-index, type of radioisotope and number of PRRT series. 133 patients (female/male 61/72) were included, median age 70 (interquartile range 64-76) years. GI-NEN comprised 62%, pancreatic 23% and BP 11%. Median Ki67-index was 5%. After first PRRTG1- and G2-tumors had PFS of 25 and 22 months, compared to 11 months in G3-NENs (p 
ISSN:0036-5521
1502-7708
DOI:10.1080/00365521.2021.1872095